I
Iphigenia Koumenis
Researcher at Genentech
Publications - 16
Citations - 2573
Iphigenia Koumenis is an academic researcher from Genentech. The author has contributed to research in topics: Conjugate & Tissue factor. The author has an hindex of 8, co-authored 15 publications receiving 2514 citations.
Papers
More filters
Journal ArticleDOI
Safety and antitumor activity of recombinant soluble Apo2 ligand
Avi Ashkenazi,Roger Pai,Sharon Fong,Susan Leung,David A. Lawrence,Scot A. Marsters,Christine Blackie,Ling Chang,Amy E. McMurtrey,Andrea Hebert,Laura DeForge,Iphigenia Koumenis,Derf Lewis,Louise A. Harris,Jeanine L. Bussiere,Hartmut Koeppen,Zahra Shahrokh,Ralph H. Schwall +17 more
TL;DR: Apo2L may have potent anticancer activity without significant toxicity toward normal tissues, and cooperated synergistically with the chemotherapeutic drugs 5-fluorouracil or CPT-11, causing substantial tumor regression or complete tumor ablation.
Journal ArticleDOI
Adapting pharmacokinetic properties of a humanized anti-interleukin-8 antibody for therapeutic applications using site-specific pegylation.
Steven R. Leong,Laura DeForge,Leonard G. Presta,Tania Gonzalez,Audrey Fan,Marcel Reichert,Anan Chuntharapai,K. Jin Kim,Daniel Tumas,Wyne P. Lee,Peter Gribling,Brad Snedecor,Han Chen,Vanessa Hsei,Monika B. Schoenhoff,Victoria Hale,James Deveney,Iphigenia Koumenis,Zahra Shahrokh,Patrick McKay,Walter Galan,Brian Wagner,Daljit S. Narindray,Caroline Hebert,Gerardo A. Zapata +24 more
TL;DR: It is demonstrated that it is possible to customize the pharmacokinetic properties of a Fab' while retaining its antigen binding activity and all PEGylated Fab' molecules were as efficacious in reducing oedema as the original monoclonal antibody.
Journal ArticleDOI
Modulating pharmacokinetics of an anti-interleukin-8 F(ab′)2 by amine-specific PEGylation with preserved bioactivity
Iphigenia Koumenis,Zahra Shahrokh,Steven R. Leong,Vanessa Hsei,Laura DeForge,Gerardo A. Zapata +5 more
TL;DR: This study shows that by attaching high molecular weight PEGs at a one or two sites, bioactive antibody fragments can be made reproducibly with sizes tailored to achieve the desired pharmacokinetics.
Patent
Antibody fragment-polymer conjugates and uses of same
TL;DR: In this paper, the authors describe conjugates formed by an antibody fragment covalently attached to a non-proteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD.
Patent
Antibody fragment-polymer conjugates and humanized anti-il-8 monoclonal antibodies
Vanessa Hsei,Iphigenia Koumenis,Steven R. Leong,Leonard G. Presta,Zahra Shahrokh,Gerarado A. Zapata +5 more
TL;DR: In this article, a humanized anti-IL-8 monoclonal antibody and variants thereof are described for use in diagnostic applications and in the treatment of inflammatory disorders, and a conjugate formed by an antibody fragment covalently attached to a non-proteinaceous polymer is described.